Plasma Membrane Proteomics of Tumor Spheres Identify CD166 as a Novel Marker for Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma*

Patients with advanced head and neck squamous cell carcinoma (HNSCC) have a poor prognosis with the currently available therapy, and tumor recurrence is frequently observed. The discovery of specific membrane-associated cancer stem cell (CSC) markers is crucial for the development of novel therapeutic strategies to target these CSCs. To address this issue, we established sphere cultures to enrich CSCs and used them for plasma membrane proteomics to identify specific membrane signatures of the HNSCC spheres. Of a dataset that included a total of 376 identified proteins, 200 were bona fide membrane proteins. Among them, 123 proteins were at least 1.5-fold up- or down-regulated in the spheres relative to the adherent cultures. These proteins included cell adhesion molecules, receptors, and transporter proteins. Some of them play key roles in wnt, integrin, and TGFβ signaling pathways. When we compared our dataset with two published hESC membrane protein signatures, we found 18 proteins common to all three of the databases. CD166 and CD44 were two such proteins. Interestingly, the expression of CD166, rather than that of the well-established HNSCC CSC marker CD44, was significantly related to the malignant behavior of HNSCC. Relative to CD166low HNSCC cells, CD166high HNSCC cells had a greater sphere-formation ability in vitro and tumor formation ability in vivo. Patients whose tumors expressed high levels of CD166 had a significantly poorer clinical outcome than those whose tumors expressed low levels of CD166 (cohort 1: 96 cases, p = 0.040), whereas the level of CD44 expression had only a marginal influence on the clinical outcome of patients with HNSCC (p = 0.078). The level of CD166 expression in HNSCC tumors was also associated with the tumor recurrence rate (cohort 2: 104 cases, p = 0.016). This study demonstrates that CD166 is a valuable cell surface marker for the enrichment of HNSCC stem cells and that plasma membrane proteomics is a promising biological tool for investigating the membrane proteins of CSCs.

[1]  G. Sauter,et al.  ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients , 2012, International journal of cancer.

[2]  H. Clevers,et al.  Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target* , 2011, Molecular & Cellular Proteomics.

[3]  Bin Gu,et al.  Proteomic Analyses Reveal Common Promiscuous Patterns of Cell Surface Proteins on Human Embryonic Stem Cells and Sperms , 2011, PloS one.

[4]  Hans Clevers,et al.  The cancer stem cell: premises, promises and challenges , 2011, Nature Medicine.

[5]  M. Hummel,et al.  Evidence for Epithelial-Mesenchymal Transition in Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma , 2011, PloS one.

[6]  F. Jänicke,et al.  Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin , 2011, Journal of Clinical Pathology.

[7]  M. Wong,et al.  Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. , 2010, Gastroenterology.

[8]  S. Morrison,et al.  Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. , 2010, Cancer cell.

[9]  G. Mælandsmo,et al.  A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth , 2010, Cancer Immunology, Immunotherapy.

[10]  H. Friess,et al.  ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer , 2010, Journal of surgical oncology.

[11]  P. Slootweg,et al.  Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma. , 2010, Oral oncology.

[12]  W. Jiang,et al.  ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis. , 2010, Anticancer research.

[13]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[14]  M. Koch,et al.  Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse , 2009, British Journal of Cancer.

[15]  E. Diamandis,et al.  Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer , 2009, International journal of cancer.

[16]  R. Ralhan,et al.  Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients , 2009, International journal of cancer.

[17]  Ole N Jensen,et al.  Metastasis-related Plasma Membrane Proteins of Human Breast Cancer Cells Identified by Comparative Quantitative Mass Spectrometry* , 2009, Molecular & Cellular Proteomics.

[18]  Hans Clevers,et al.  Crypt stem cells as the cells-of-origin of intestinal cancer , 2009, Nature.

[19]  B. Mack,et al.  CD44s and CD44v6 Expression in Head and Neck Epithelia , 2008, PloS one.

[20]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[21]  S. Canevari,et al.  Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients , 2008, Clinical Cancer Research.

[22]  E. Diamandis,et al.  Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines , 2007, Molecular & Cellular Proteomics.

[23]  J. McNamara Cancer Stem Cells , 2007, Methods in Molecular Biology.

[24]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Michael F. Clarke,et al.  Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.

[26]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[27]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[28]  M. Noble,et al.  Cancer stem cells. , 2006, The New England journal of medicine.

[29]  P. Walczak,et al.  Human Umbilical Cord Blood Progenitors: The Potential of These Hematopoietic Cells to Become Neural , 2005, Stem cells.

[30]  A. Verma,et al.  MEMD/ALCAM: A Potential Marker for Tumor Invasion and Nodal Metastasis in Esophageal Squamous Cell Carcinoma , 2005, Oncology.

[31]  G. Swart,et al.  Activated leukocyte cell adhesion molecule (ALCAM/CD166): Signaling at the divide of melanoma cell clustering and cell migration? , 2005, Cancer and Metastasis Reviews.

[32]  Christian Pilarsky,et al.  Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival , 2005, The Journal of pathology.

[33]  M. Lotz,et al.  Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. , 2004, Arthritis and rheumatism.

[34]  S. Fujii,et al.  Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). , 2003, The Journal of clinical endocrinology and metabolism.

[35]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  T. Shibahara,et al.  The presence of candidate tumor suppressor gene loci at chromosome 3p for oral squamous cell carcinomas. , 2002, Oral oncology.

[37]  C. Sato,et al.  Neuronal Differentiation-dependent Expression of the Disialic Acid Epitope on CD166 and Its Involvement in Neurite Formation in Neuro2A Cells* , 2002, The Journal of Biological Chemistry.

[38]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[39]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[40]  Shuping Zhao,et al.  Increased expression of stem cell markers in malignant melanoma , 2007, Modern Pathology.

[41]  S. Loening,et al.  ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions , 2003, The Prostate.

[42]  Troy Stevens,et al.  Open Access Activated Leukocyte Cell Adhesion Molecule in Breast Cancer: Prognostic Indicator , 2022 .